A targeted antibacterial biodegradable microneedle, its preparation method and application

By using targeted antibacterial biodegradable microneedles, alkaloids, flavonoids, anthraquinones, and phenolic acids are used to regulate the mechanical interaction between host cells and bacteria, solving the treatment challenges of skin bacterial infections in existing technologies and achieving highly efficient and safe anti-infection effects.

CN123101451APending Publication Date: 2026-11-17AFFILIATED HOSPITAL OF INNER MONGOLIA MEDICAL UNIV (INNER MONGOLIA AUTONOMOUS REGION CARDIOVASCULAR INST)
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202611494706.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-09-23
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

Current technology lacks a novel anti-infective agent that can effectively treat bacterial skin infections, reduce the risk of drug resistance, and has well-defined and controllable quality and excellent delivery efficiency, especially against methicillin-resistant Staphylococcus aureus (MRSA) infections.

Method used

A targeted antibacterial biodegradable microneedle was developed, which uses active ingredients composed of alkaloids, flavonoids, anthraquinones and phenolic acids to reduce bacterial adhesion by regulating the mechanical interaction between host cells and bacteria, and is then precisely delivered transdermally by encapsulating the microneedles with PLGA and hyaluronic acid.

Benefits of technology

It significantly reduces bacterial adhesion to host cells, inhibits bacterial colonization, reduces the risk of drug resistance, has good biosafety and delivery efficiency, is superior to traditional topical preparations, and is suitable for treating drug-resistant bacterial infections.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure FT_1
    Figure FT_1
  • Figure FT_2
    Figure FT_2
  • Figure FT_3
    Figure FT_3
Patent Text Reader

Abstract

This application discloses a targeted antibacterial biodegradable microneedle, its preparation method, and its application. The microneedle body is composed of a biodegradable matrix material, and an active ingredient is embedded within the body. The active ingredient is configured to be released upon degradation of the microneedle body. The active ingredient is a host-directed antibacterial composition with a synergistic antibacterial effect (FIC Index ≤ 0.5). It inhibits bacterial colonization by regulating the mechanical interaction between host cells and bacteria and reducing bacterial adhesion to host cells. This application is based on a novel host-directed antibacterial strategy, which does not directly kill bacteria but rather reduces bacterial adhesion and inhibits colonization by regulating the mechanical interaction between host cells and bacteria. It provides a targeted antibacterial biodegradable microneedle, its preparation method, and its application that can effectively treat bacterial skin infections, reduce the risk of drug resistance at the mechanistic level, and has clearly controllable quality and excellent delivery efficiency.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to the fields of pharmaceutical preparations and biomedical materials, specifically to a targeted antibacterial biodegradable microneedle, its preparation method and application, and more particularly to a targeted antibacterial biodegradable microneedle for treating bacterial skin infections, its preparation method and application. Background Technology

[0002] Skin bacterial infections are common clinical conditions, primarily caused by pathogens such as Staphylococcus aureus and Streptococcus. These infections can manifest as mild local symptoms like pustules and cellulitis, or in severe cases, lead to systemic infections, posing a serious threat to human health. Currently, antibiotic treatment remains the primary clinical approach. However, with the widespread use of antibiotics, bacterial resistance has become an increasingly serious problem, particularly the emergence and spread of methicillin-resistant Staphylococcus aureus (MRSA), which has significantly reduced the efficacy of traditional antibiotics. MRSA not only spreads within hospitals but is also gradually becoming a major pathogen causing community-acquired infections, posing a significant challenge to clinical anti-infective therapy. Therefore, developing novel, highly effective, and less likely to induce resistance-inducing anti-infective drugs and strategies has become a critical issue urgently needing to be addressed in the medical field.

[0003] To address the aforementioned issues, academia and industry have conducted extensive research. For example, the study "Dalbavancin for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in pediatric patients: a case series" (Infezioni in Medicina, 2024, Vol. 32, No. 2, pp. 231-240) reported that dalbavancin, a long-acting lipoglycopeptide antibiotic, showed good efficacy and low side effects in treating acute bacterial skin and skin structure infections. However, this regimen is essentially still a traditional antibiotic therapy that directly kills bacteria, and long-term use still carries the risk of inducing drug resistance.

[0004] In the field of drug delivery technology, microneedling technology has developed rapidly since its concept was proposed in the late 1990s, evolving from first-generation solid silicon microneedles and second-generation coated microneedles to third-generation dissolvable / degradable microneedles and fourth-generation hollow microneedles. Among them, degradable microneedles have become a research hotspot for delivering biomolecules (such as vaccines and insulin) and chemical drugs due to their excellent biocompatibility, controllable drug release kinetics, and minimally invasive and painless characteristics. In the field of anti-infectives, there are already research reports on the application of microneedling technology in the treatment of skin and soft tissue infections. For example, the studies "Dual-domain engineered exosome-based self-powered microneedle delivery platform for the treatment of infected wounds" (Materials Today Bio, 2025, Vol. 35, p. 102383) and "Sulfated polysaccharide facilitates macrophage-Treg crosstalk to mitigate chronic inflammation in diabetic wound healing" (Bioactive Materials, 2025, Vol. 55, pp. 640-657) reported microneedle delivery systems loaded with antibiotics or antifungal drugs. However, most of these studies used traditional antibiotics as the loaded drugs, and their antibacterial mechanisms still relied on direct killing, failing to address the root cause of bacterial resistance.

[0005] In the search for novel antibacterial strategies, the extraction of lead compounds or effective compound formulations from traditional ethnic medicines has become an internationally recognized and effective approach. Traditional medicines, through long-term clinical practice, have accumulated rich experience in combating infection, and their multi-component, multi-target characteristics may make them less prone to inducing bacterial resistance. The Mongolian medicine Bater-7, first recorded in the *Mongolian Medical Classic*, is composed of aconite leaves, chebula, black clover, madder root, tung oil, musk, and cinnabar, possessing heat-clearing, detoxifying, and anti-inflammatory effects. Its main components, such as aconitine and gallic acid, have been reported to have antibacterial activity. However, as a traditional compound formulation, Bater-7 has a complex chemical composition, unclear interactions between its components, difficulties in quality control, and its antibacterial mechanism has not yet been systematically elucidated from a modern medical perspective. These factors severely restrict the modern application and clinical translation of Bater-7 in the field of anti-infection.

[0006] In summary, there is currently a lack of novel anti-infective agents that can effectively treat bacterial skin infections, reduce the risk of drug resistance at the mechanism level, and have clearly controllable quality and excellent delivery efficiency. Summary of the Invention

[0007] This application is based on a novel host-directed antibacterial strategy, which does not directly kill bacteria, but rather inhibits bacterial colonization by modulating the mechanical interaction between host cells and bacteria, thereby reducing bacterial adhesion. A group of synergistic compounds composed of single compounds was successfully discovered and optimized from Batzhi-7, which exerts potent anti-infective effects through this novel mechanism. Based on this, a biodegradable microneedle formulation for precise delivery of this composition was developed, effectively solving problems such as antibiotic resistance and the modernization of Mongolian medicine in existing technologies.

[0008] According to one aspect of this application, a host-directed antibacterial agent derived from traditional Mongolian medicine, but with clearly defined components, a novel mechanism, and excellent anti-infective effects, is provided, namely, a targeted antibacterial biodegradable microneedle, to achieve precise transdermal delivery. The microneedle's needle body is composed of a biodegradable matrix material, and the active ingredient is embedded within the needle body. The active ingredient is configured to be released during needle degradation. The active ingredient is a host-directed antimicrobial composition. The active ingredient has a synergistic antimicrobial effect with a combined inhibitory concentration index ≤0.5, and can inhibit bacterial colonization by regulating the mechanical interaction between host cells and bacteria and reducing the adhesion of bacteria to host cells.

[0009] Preferably, the active ingredient is derived from the Mongolian medicine Bater-7, and the active ingredient is a composition of alkaloids, flavonoids, anthraquinones and phenolic acids. The alkaloids include aconitine, the flavonoids include quercetin, the anthraquinones include hydroxyalizarin, and the phenolic acids include gallic acid, and the mass ratio of aconitine, quercetin, hydroxyalizarin to gallic acid is (2-4):(2-4):(2-4):(1-2).

[0010] Preferably, the material of the needle matrix is ​​a mixture of polylactic acid-hydroxyacetic acid copolymer (PLGA) and hyaluronic acid (HA), wherein the mass ratio of PLGA to hyaluronic acid is (8:2) to (7:3).

[0011] Preferably, the needle matrix further contains a plasticizer, which is glycerol or polyethylene glycol, and the amount added is 5% to 10% of the total mass of the matrix material.

[0012] Preferably, the molecular weight of the PLGA is 15 kDa to 30 kDa, and the molar ratio of lactic acid to glycolic acid is 50:50 to 75:25.

[0013] Preferably, the microneedles are completely degraded in phosphate-buffered saline (PBS) at pH 7.4 at 37°C within 7 to 14 days.

[0014] According to another aspect of this application, a method for preparing the targeted antibacterial biodegradable microneedles is provided, comprising the following steps: S1, mix the matrix material containing the needle with the active ingredient to obtain a blend solution; S2, After centrifuging and degassing the blended solution, inject it into the microneedle mold; S3 is dried and cured at 20℃~35℃ and relative humidity of 30%~55%. S4, demold to obtain a biodegradable microneedle array.

[0015] Preferably, in step S3, the drying temperature is 25±2℃ and the drying time is 6 hours; The resulting microneedle array has a single needle height of 650±50μm, a base diameter of 280±20μm, and a density of 100 needles / cm. 2 .

[0016] According to another aspect of this application, the application of the aforementioned targeted antibacterial biodegradable microneedles is provided, wherein the biodegradable microneedles are used in the treatment of skin infections.

[0017] Preferably, the bacteria used to treat skin infections are Staphylococcus aureus or Escherichia coli.

[0018] According to another aspect of this application, the biodegradable microneedles are provided for use in the treatment and / or prevention of skin infections caused by Staphylococcus aureus.

[0019] Compared with the prior art, the beneficial effects of this application are as follows: This application, based on the traditional Mongolian medicine compound Bater-7, systematically screened and identified a composition of alkaloids, flavonoids, anthraquinones, and phenolic acids as the active ingredient for microneedle materials using a combination of checkerboard and response surface methodology. Checkerboard dilution experiments confirmed that the combined inhibitory concentration index (FIC Index) of the selected active ingredient was ≤0.5, demonstrating a clear synergistic antibacterial effect. Furthermore, in an in vitro HaCaT cell infection model, this active ingredient achieved an anti-infective effect comparable to the complete Bater-7 compound. Because the active ingredient is clearly identified and its quality is controllable, this application fundamentally overcomes the shortcomings of traditional Mongolian medicine compound formulas, which are difficult to precisely control in terms of composition and hinder modern formulation development.

[0020] This application is the first to propose and verify that the aforementioned active ingredient (i.e., the Batjer-7 core composition) exerts its antibacterial effect through a host-directed mechanism. Specifically, it reduces bacterial adhesion to host cells by regulating the mechanical interactions at the bacterial-host cell interface, thereby inhibiting bacterial colonization in host tissues. Compared to traditional methods of directly killing bacteria, this host-directed strategy reduces the risk of inducing bacterial resistance at the source, providing a new solution for anti-infective therapy. This application uses single-cell force spectroscopy techniques, such as atomic force microscopy (AFM), to quantitatively analyze the adhesion between individual bacteria and individual host cells before and after treatment with the Batjer-7 core composition. The results show that after treatment with the active ingredient described in this application, the bacterial-host cell adhesion is significantly reduced (e.g., reduced by at least 30%, 50%, or more), thus directly confirming from a mechanobiological perspective that this active ingredient inhibits bacterial colonization through a novel host-directed antibacterial mechanism by regulating the mechanical interactions at the host-bacterial interface.

[0021] This application also provides a method for exploring the mechanism of action of the host-guided antibacterial composition. In an infection model, both host cells treated with and untreated with the active ingredient (such as HaCaT cells) were subjected to parallel transcriptome sequencing (RNA-seq) and whole-genome CRISPR screening. By comparing the gene expression profiles of the two cell groups, differentially expressed genes were screened, and GO / KEGG enrichment analysis was used to identify signaling pathways regulated by the active ingredient related to cell adhesion, cytoskeleton remodeling, and immune response, as well as potential novel antibacterial targets, providing innovative theoretical support for the host-guided therapy.

[0022] This application achieves precise transdermal delivery of active ingredients by loading them into biodegradable microneedles with PLGA and hyaluronic acid as matrix materials and adding plasticizers.

[0023] This application optimizes the mass ratio of PLGA to hyaluronic acid to 8:2–7:3 and adds 5%–10% glycerol or polyethylene glycol as a plasticizer, resulting in a microneedle array that possesses excellent tip integrity, sharpness, and array uniformity. Mechanical testing verifies that the average puncture force of the microneedles is greater than 3.8 MPa, effectively penetrating the stratum corneum; the breaking force is greater than 13.8 MPa / needle, sufficient to ensure the mechanical integrity of the microneedles during normal operation and use, effectively avoiding the risk of needle breakage and residue.

[0024] This application prepares the microneedles using a micromolding method. By optimizing key process parameters such as centrifugation speed, centrifugation time, drying temperature, and ambient humidity, the microneedle array exhibits good tip filling integrity, achieving a batch yield of over 90%. The preparation process is stable, reliable, and highly repeatable, making it feasible for large-scale production.

[0025] The targeted antibacterial biodegradable microneedles provided in this application have been verified by in vitro and in vivo pharmacodynamic experiments. The prepared drug-loaded microneedles can significantly reduce the bacterial load in Staphylococcus aureus-infected skin tissue, reduce the degree of inflammatory cell infiltration in the infected area, and promote the healing and repair of infected wounds. At the same time, no obvious local skin irritation or systemic toxicity was observed during application, demonstrating good biosafety.

[0026] The drug-loaded microneedles of this application, through a host-guided strategy, can achieve therapeutic effects superior to traditional topical preparations such as mupirocin ointment, and have broad clinical application prospects in the treatment of skin bacterial infections, especially drug-resistant bacterial infections. Furthermore, the microneedles are extremely small in size, resulting in good patient compliance, and possess significant clinical translational value in the field of local skin anti-infection. Attached Figure Description

[0027] Figure 1 The microneedle array scanning electron microscope (SEM) morphology image prepared in Example 3; Figure 2 Mechanical compression performance test curves for microneedles with different formulations; Figure 3 This is a graph showing the results of the bacterial-host cell adhesion test in Example 7; Figure 4 This is a high-performance liquid chromatography (HPLC) chromatogram of the active composition of the present invention; Figure 5 A graph showing the results of flow cytometry detection of bacterial infection in host cells; Figure 6 Immunofluorescence staining micrographs and quantitative analysis diagrams of bacterial infection of host cells; Figure 7 Photographs of colony count results on in vitro antibacterial plates; Figure 8 This is a graph showing the results of the rat cardiac safety evaluation. Figure 9 Photographs of bacterial load plate counts on infected skin wounds in rats; Figure 10 Photographs showing the healing process of infected skin wounds in rats; Figure 11 The image shows a product of the targeted antibacterial biodegradable microneedles prepared in this application. Figure 12 for Figure 5 Enlarged schematic diagrams of the SSC-A / FITC-A scatter plots of the upper and middle groups and the corresponding FITC-A single-parameter histograms in the middle; Figure 13 for Figure 6 An enlarged view of the statistical bar chart on the right side of the middle section, showing the infection rate of Staphylococcus aureus. Detailed Implementation

[0028] According to one embodiment of this application, a targeted antibacterial biodegradable microneedle is provided, wherein the needle body of the microneedle is composed of a biodegradable matrix material, and an active ingredient is embedded in the needle body; The active ingredient is configured to be released during needle degradation. The active ingredient is a host-directed antimicrobial composition. The active ingredient has a synergistic antimicrobial effect with a combined inhibitory concentration index ≤0.5, and can inhibit bacterial colonization by regulating the mechanical interaction between host cells and bacteria and reducing the adhesion of bacteria to host cells.

[0029] In this application, the active ingredient is derived from the Mongolian medicine Bater-7, and the active ingredient is a composition of alkaloids, flavonoids, anthraquinones and phenolic acids. The alkaloids include aconitine, the flavonoids include quercetin, the anthraquinones include hydroxyalizarin, and the phenolic acids include gallic acid, and the mass ratio of aconitine, quercetin, hydroxyalizarin to gallic acid is (2-4):(2-4):(2-4):(1-2).

[0030] In this application, the material of the needle matrix is ​​a mixture of polylactic acid-hydroxyacetic acid copolymer (PLGA) and hyaluronic acid (HA), wherein the mass ratio of PLGA to hyaluronic acid is (8:2) to (7:3).

[0031] The needle matrix also contains a plasticizer, which is glycerol or polyethylene glycol, and the amount added is 5% to 10% of the total mass of the matrix material.

[0032] The PLGA has a molecular weight of 15 kDa to 30 kDa and a molar ratio of lactic acid to glycolic acid of 50:50 to 75:25.

[0033] It should be noted that: In this application, the active ingredient of the microneedle is a composition of host-directed antibacterial compounds, in which alkaloids, flavonoids, and polyphenols in Batjla-7 play a key role. In this application, by combining the checkerboard method and response surface methodology, the optimal combination and mass ratio of the alkaloids, flavonoids, anthraquinones, and phenolic acids in a HaCaT infection model were determined using the fractional inhibitory concentration index (FIC Index) against Staphylococcus aureus as evaluation indicators. The optimal ratio is (2-4):(2-4):(2-4):(1-2). Furthermore, the combined fractional inhibitory concentration index (FIC Index) of the active ingredients is ≤ 0.5. The active ingredients can significantly reduce the adhesion of bacteria to host cells, making them a typical host-directed antibacterial agent.

[0034] The molar ratio of lactic acid to glycolic acid mentioned in this invention refers to the molar ratio of structural units constituting the polymer chain of polylactic-co-glycolic acid copolymer (PLGA), rather than the content ratio of free lactic acid or free glycolic acid monomers in the finished polymer. This ratio is controlled by the feed ratio of lactide to glycolide during polymerization.

[0035] The needle matrix is ​​a mixture of PLGA and hyaluronic acid in a mass ratio of (8:2) to (7:3). This matrix exhibits good mechanical properties, biocompatibility, and controllable degradation. 5%–10% glycerol or polyethylene glycol is added to the matrix as a plasticizer to optimize the microneedle's toughness and puncture performance.

[0036] The microneedles were completely degraded in phosphate-buffered saline (PBS) at pH 7.4 at 37°C within 7 to 14 days.

[0037] According to another embodiment of this application, a method for preparing the biodegradable microneedles is provided, comprising the following steps: S1, mix the matrix material containing the needle with the active ingredient to obtain a blend solution; S2, After centrifuging and degassing the blended solution, inject it into the microneedle mold; S3 is dried and cured at 20℃~35℃ and relative humidity 30%~55%, with the preferred drying temperature being 25±2℃ and the drying time being 6 hours; S4, demold to obtain a biodegradable microneedle array.

[0038] The fabricated microneedle array has a single needle height of 650 μm, a base diameter of 280 μm, and a density of 100 needles / cm. 2 .

[0039] It should be noted that: The microneedles were prepared using a micromolding method. The process involved mixing the active ingredient with a matrix solution, centrifuging to remove bubbles, injecting the mixture into a PDMS mold, vacuum-assisted or centrifugation-assisted filling, drying at 25±2℃ and 45±5% relative humidity for 6 hours, and then demolding. The resulting microneedle array had a single needle height of 650±50μm, a base diameter of 280±20μm, and a density of 100 needles / cm². 2 The average breaking force is >13.8 MPa / needle, and the average puncture force is >3.8 MPa, fully meeting the requirements for penetrating the stratum corneum. Specifically: (1) Design and processing of precision molds (determining basic dimensions) A silicon master substrate was fabricated using a photolithography-electroforming-molding (LIGA) process, which was then used to create a polydimethylsiloxane (PDMS) female mold. To achieve a finished needle height of 650±50 μm, the needle cavity depth of the PDMS mold had to be designed to be an initial depth of 800±50 μm. This is because the volume shrinkage rate of the PLGA / HA composite material is approximately 15%~20% during solvent (such as dichloromethane or water) evaporation. The mold bottom diameter was designed to be 320±20 μm, with a target bottom diameter shrinkage to 280±20 μm.

[0040] (2) Centrifugation-assisted filling parameter optimization (ensuring needle tip integrity and density): After the blended solution (viscosity controlled at 300-500 cP) is injected into the PDMS mold, it must be centrifuged in a stepped manner rather than at a constant speed to ensure the high-density array (100 needles / cm²). 2 The needle tip is free of air bubbles and the filling is dense: First stage (low-speed spreading): Centrifuge at 500 rpm for 3 minutes to ensure the solution evenly covers the mold surface and prevent air bubbles from remaining on a large area of ​​the substrate.

[0041] The second stage (high-speed filling): centrifugation at 3500~4000 rpm for 15 minutes. The powerful centrifugal force compels the high-viscosity polymer solution to flow into the bottom of the microporous needle tip, which is up to 800 μm deep. This step is crucial to ensuring that the needle tip is sharp and free of defects.

[0042] (3) Gradient drying and curing process (determines final geometric convergence) In order to eliminate the "coffee ring effect" or needle indentation caused by rapid solvent evaporation, segmented temperature and humidity controlled drying is adopted: Pre-curing stage: Temperature 15~20℃, relative humidity 55~60%, maintained for 2 hours. This stage allows the solvent to evaporate slowly, and the polymer chain segments to initially stack.

[0043] Main curing stage: temperature 25±2℃, relative humidity 35~40%, maintained for 6 hours (i.e., the preferred conditions in the original claim). Lower humidity accelerates solvent evaporation, promoting the hardening and shaping of the needle.

[0044] (4) Demolding and post-processing. The resulting product is as follows: Figure 11 As shown.

[0045] According to another embodiment of this application, an application of the aforementioned targeted antibacterial biodegradable microneedles is provided, specifically its application in treating skin infections. The bacteria used in treating skin infections are Staphylococcus aureus or Escherichia coli.

[0046] According to another embodiment of this application, an application of a biodegradable microneedle is provided for the treatment and / or prevention of skin infections caused by Staphylococcus aureus. In a rat skin infection model, the drug-loaded microneedles of this invention are significantly more effective than traditional ointments in reducing bacterial load in infected tissues and promoting wound healing.

[0047] The present application is described in detail below with reference to the embodiments, but the present application is not limited to these embodiments. It should be noted that the Mongolian medicine Bater-7 in the following embodiments, batch number: 20250110; filing number: Inner Mongolia Medicine Preparation Certificate M20210146000; was purchased from the National Mongolian Medicine Preparation Center of Inner Mongolia International Mongolian Medicine Hospital; the standard products: hydroxyalizarin 111898-201102; quercetin 100081-202411; gallic acid 110831-201204, were purchased from the China National Institutes for Food and Drug Control, with HPLC purity ≥98%; aconitine 302-27-2 was purchased from Manster (Chengdu) Biotechnology Co., Ltd.

[0048] Preparation of WQH composition: Take standard aconitine, quercetin, hydroxyalizarin and gallic acid, mix them in a mass ratio of 3:3:3:1.5 to obtain WQH composition, seal and store in the dark at 4 ℃.

[0049] The specific preparation process of the PLGA / HA stable blend solution is as follows: Raw material specifications: PLGA weight average molecular weight 20 kDa, lactic acid / glycolic acid molar ratio 50:50; hyaluronic acid molecular weight 50 kDa; plasticizer glycerin, added at 8% of the total matrix mass.

[0050] Organic phase preparation: PLGA was dissolved in dichloromethane at room temperature with stirring to prepare a 30% (w / v) organic stock solution; Aqueous phase preparation: Dissolve hyaluronic acid in deionized water with stirring to prepare a 10% (w / v) aqueous stock solution; dissolve the WQH composition in anhydrous ethanol beforehand to aid dissolution, and add it to the aqueous phase after complete dissolution and mix well; Emulsification and blending: The organic phase of PLGA and the aqueous phase of HA were mixed at a mass ratio of 7:3 and stirred at 3000 r / min for 30 min in a high-speed emulsifier; glycerol plasticizer was added to adjust the solid content of the system to 20% (w / v) and stirred until the viscosity of the system stabilized at 400 cP; Storage requirements: The blended solution is stable at room temperature and protected from light for 4 hours. After 4 hours, the system will separate and become ineffective. It must be prepared and used immediately.

[0051] Example 1: Verification of the compounds in the active ingredient and the proportions of each compound.

[0052] 1.1 Method Selection: In this embodiment, the checkerboard assay and response surface methodology (RSM) were combined to systematically screen the single compounds that played a key role in the previous Batge-7 assay and determine the optimal ratio of the four monomers.

[0053] 1.2 Sample Preparation: The purified aconitine, quercetin, hydroxyalizarin, and gallic acid were dissolved in a small amount of DMSO to prepare high-concentration stock solutions. Before use, each stock solution was diluted to the required working concentration with cell culture medium or bacterial culture medium, and the final volume concentration of DMSO in all treatment groups (including single drug groups, compound groups, and Batge-7 whole extract groups) was ensured not to exceed 0.1% to eliminate the influence of the solvent on the experimental results.

[0054] 1.3 Experimental Design: (1) Initial screening: checkerboard micro-broth dilution method, drug concentration gradient of 0.125~64 μg / mL in 96-well plates; single monomer group, binary / ternary compound group, Batge-7 full extract group, blank culture medium control group (culture medium without drug).

[0055] The evaluation metrics in this embodiment include: MIC value, combined antibacterial concentration index (FIC Index), cell viability, and bacterial invasion inhibition rate.

[0056] MIC determination: The micro-broth dilution method was used. Different drug combinations prepared according to the experimental design (aconitine: hydroxyalizarin: quercetin: gallic acid = 2:2:2:1) were added to Luria Bertany medium (LB medium) containing bacteria. After incubation at 37°C for 18-24 hours, the minimum drug concentration that completely inhibited bacterial growth was observed with the naked eye, which was the MIC value.

[0057] The combined inhibitory concentration index (FIC Index) is calculated, and the judgment criteria are as follows: FIC Index ≤ 0.5: synergistic effect; FIC Index > 0.5 and ≤ 4.0: no effect; FIC Index > 4.0: antagonistic effect.

[0058] (2) Fine screening, using response surface methodology: Based on the initial screening results, combinations and concentration ranges with synergistic trends were selected. Multiple experimental schemes with different ratios were generated using a central composite design or Box-Behnken design. Specifically, a mathematical model was established with the mass ratio of the four monomers as independent variables and the FIC index and the HaCaT cell bacterial invasion inhibition rate as dual response indicators.

[0059] 1.4 Strain selection: Staphylococcus aureus ATCC 25923 and Escherichia coli ATCC 25922 were selected as standard test strains.

[0060] 1.5 Validation of the HaCaT cell infection model: HaCaT cells were plated to 80% confluence and co-incubated with Staphylococcus aureus at MOI=10 for 2 h to establish a bacterial model. Extracellular bacteria were killed using 100 μg / mL gentamicin, and the lysed cells were plated for intracellular viable count. Bacterial invasion inhibition rate: The effectiveness of gentamicin in killing extracellular bacteria was determined using an antibiotic protection assay by plating the supernatant of the culture medium. After killing extracellular bacteria with gentamicin (100 μg / mL), host cells were lysed, and the lysate was plated for colony counting. The number of intracellular bacteria and the corresponding invasion inhibition rate were calculated. The survival rate of host cells after drug treatment was determined using the CCK-8 assay.

[0061] 1.6 Data Analysis Using Design-Expert software to fit the model, the optimal ratio range was determined by combining four indicators: MIC, combined antibacterial concentration index, bacterial invasion inhibition rate, and cell survival rate. The mass ratio of aconitine, quercetin, hydroxyalizarin to gallic acid was (2-4):(2-4):(2-4):(1-2), with the optimal ratio at the center being 3:3:3:1.5.

[0062] The optimal ratio of the quaternary composition has a combined antibacterial concentration index (FIC index) of 0.38 (FIC Index ≤ 0.5), exhibiting a significant synergistic antibacterial effect; the bacterial invasion inhibition rate is > 75%, and the cell survival rate after infection is significantly higher than that of any single monomer and the whole extract of Batzhi-7.

[0063] Example 2: Qualitative identification of the active composition by HPLC and compatibility test of excipients.

[0064] In this embodiment, the active ingredients, namely the four active ingredients aconitine, quercetin, hydroxyalizarin, and gallic acid obtained from the optimal compound combination screened in Example 1, were qualitatively identified by HPLC, providing key parameter basis for the subsequent screening of microneedle prescriptions.

[0065] 2.1 HPLC Qualitative Identification Test: Experimental instruments: Agilent 1260 high performance liquid chromatograph; C18 reversed-phase column; mobile phase: methanol-0.1% phosphoric acid aqueous solution gradient elution; detection wavelength: 260 nm; column temperature: 30 ℃; flow rate: 1.0 mL / min; injection volume: 20 μL.

[0066] Experimental groups: blank PLGA / HA matrix extract group, mixed solution of four monomer standards group, and drug-loaded microneedle extract test solution of WQH composition group.

[0067] Among them, the blank matrix extract group was used to exclude chromatographic interference from PLGA, hyaluronic acid, and plasticizer excipients; the mixed solution of four monomer standards was used as a reference for the peak shape and retention time of the four active ingredients; and the WQH composition drug-loaded microneedle extraction test solution group was used to verify the stable existence of active ingredients in the microneedles.

[0068] The operation procedure is as follows: Configure the corresponding mobile phase, set the detection wavelength, and sequentially inject samples to collect chromatograms. Compare the retention times of characteristic peaks in each group. The relative deviation between the characteristic peaks of the test sample and the standard should be ≤5%, with no interference from excipient peaks. Figure 4 The image shows the high-performance liquid chromatography (HPLC) chromatogram of the drug composition loaded on microneedles in the examples. The horizontal axis represents time (in minutes), and the vertical axis represents signal intensity (in cps). Qualitative analysis of the active composition of this invention revealed multiple sets of symmetrical characteristic chromatographic peaks without severe tailing, and no interfering peaks corresponding to the blank excipients. The relative deviation between the retention time of the test sample peak and the retention time of the standard peak was ≤5%, indicating that the corresponding active ingredient was stably present. The microneedle dissolution and drying processes did not damage the four types of active ingredients, and the active ingredients could be stably embedded within the composite matrix, proving that the active ingredients were chemically stable during microneedle preparation and successfully loaded into the needle body. Therefore, it can be concluded that the active ingredients did not degrade throughout the entire microneedle preparation and drying process, and a fingerprint chromatographic quality control standard can be established based on HPLC.

[0069] 2.2 Compatibility verification of the selected active ingredient with the needle matrix material: The selected active ingredient WQH composition was physically mixed with candidate microneedle excipients, such as PLGA, hyaluronic acid (HA), and glycerin, in a certain proportion, and then subjected to accelerated high-temperature and high-humidity storage at 40 ℃ and 75% RH for 14 days. Simultaneously, visual observation, HPLC impurity detection, and DSC differential scanning calorimetry were performed to detect any changes in melting point or thermal behavior. The results showed no new degradation products, no melting point shift, and good excipient compatibility. This example verifies that there are no significant physicochemical interactions between the WQH composition and the various excipient combinations. This provides a complete database of physicochemical parameters for microneedle formulation design.

[0070] Example 3: Microneedle array SEM morphology characterization experiment.

[0071] This embodiment demonstrates the SEM morphology characterization of the microneedles described in this application. Based on the observation of the overall and individual microscopic morphology of the PLGA / HA composite matrix microneedle array, the needle-forming performance of the composite matrix and preparation process of this invention is verified, supporting the structural basis for the microneedles to penetrate the stratum corneum.

[0072] 3.1 Experimental instruments and materials: Scanning electron microscope, ion sputtering gold instrument; three independent fields of view in the middle and edge of the array for each group of samples.

[0073] 3.2 Experimental Groups: Pure PLGA blank microneedles (negative control); Pure HA blank microneedles (negative control); Blank composite matrix microneedles (PLGA:HA=7:3, glycerol 8%, drug-free) (control); Drug-loaded microneedles of the optimal formulation WQH composition of this invention (PLGA:HA=7:3, glycerol 8%) (experimental group). The pure PLGA microneedle group served as a single polymer matrix reference, used to compare the advantages of composite matrix molding; the pure HA microneedle group served as a single hydrophilic excipient reference, used to verify the improvement of collapse defects by the polymer composite matrix.

[0074] 3.3 Standardized Complete Operation: Cut neatly shaped microneedles, apply them smoothly to the sample stage with conductive adhesive, and ion-spray gold for 3 minutes to eliminate static electricity. Capture the entire array at low magnification (1 mm scale bar) and capture magnified images of individual needles at high magnification (300 μm scale bar). For each sample group, capture three independent fields of view: the center and edge of the array. Combine these images to form an appendix. Figure 1 .

[0075] Figure 1 includes two views: a low-magnification overall view (scale bar 1 mm) showing the microneedles arranged in a uniform and regular matrix without large areas of missing needles; and a magnified view of a single microneedle (scale bar 300 μm) on the left, showing a standard conical shape with a sharp tip and a smooth surface, free from defects such as collapse, holes, burrs, or broken needles. This demonstrates that the needle-forming performance of the PLGA / HA blank composite matrix microneedles of this invention is significantly superior to that of pure PLGA and pure HA single-component matrices. Furthermore, even after adding the active ingredient WQH composition, the drug-loaded microneedles maintain a good morphology. The complete conical microneedles possess the structural conditions to penetrate the stratum corneum of the skin, meeting the requirements for transdermal drug delivery.

[0076] Example 4: Verification of matrix material ratio, molecular weight and in vitro degradation of the biodegradable loaded microneedles of this application.

[0077] 4.1 Experimental Design and Recipe Investigation: Design multiple alternative formulation options and systematically examine the effects of the following variables on microneedle formation and performance: 4.2 Variable Settings: (1) Material type and proportion: PLGA Type 1: Lactic acid / glycolic acid molar ratio 50:50, molecular weight 15 kDa; PLGA Type 2: Lactic acid / glycolic acid molar ratio 75:25, molecular weight 30 kDa; Hyaluronic acid (HA) molecular weight range: 10 kDa~100 kDa; gelatin; The study examines single-material and composite material systems, with composite system formulations such as PLGA and HA having mass ratios of 8:2 and 7:3.

[0078] (2) Additives: 5% to 10% (by mass) of glycerol was added as a plasticizer to the above-mentioned PLGA type 1 and PLGA type 2 formulations to improve the flexibility of the microneedles.

[0079] Preparation and evaluation of pure HA blank microneedles: 4.3 Evaluation Indicators: Blank microneedles for each formulation were initially prepared using micromolding, and their performance was evaluated as follows: Needle formation evaluation: The morphology of each group of microneedles was directly observed using a scanning electron microscope (SEM). Evaluation criteria included: whether the needle body shape was complete, whether the needle tip was sharp, and whether the array arrangement was uniform.

[0080] Mechanical strength determination: A microcomputer-controlled electronic universal testing machine, such as the STS 10 N model, was used to perform pressure testing on the microneedle array. The test parameters were: probe descent speed 10 mm / min, tested until the mechanical threshold at which the needle body fractured. The breaking force of the microneedle array was recorded. The acceptance criterion was set as an average breaking strength > 100 MPa.

[0081] Degradation curve of PBS at 37 ℃ and pH 7.4.

[0082] 4.4 Investigation of in vitro degradation behavior: Each group of blank microneedles was immersed in PBS buffer (pH 7.4) at 37°C with continuous shaking. Samples were taken at 7, 10, and 14 days and dried to constant weight. The weight loss rate was calculated, and the SEM morphology after degradation was simultaneously photographed. Pure HA microneedles were completely eroded and needle-free at 3 days; pure PLGA microneedles still retained an intact needle outline at 14 days; the PLGA:HA=7:3 composite matrix was completely degraded at 10 days, and the PLGA:HA=8:2 composite matrix was completely degraded at 13 days, completely covering the degradation range of 7–14 days.

[0083] Screening conclusions: The optimal matrix range is PLGA molecular weight of 15 kDa~30 kDa, LA:GA molar ratio of 50:50~75:25, PLGA:HA mass ratio of 8:2~7:3, and plasticizer addition of 5%~10%.

[0084] Example 5: This example is based on the optimal matrix material screened in Example 4, and the microneedle prescription is optimized and verified by single-factor combined response surface methodology.

[0085] 5.1 Investigation of variables in single-factor experiments: With other preparation conditions kept constant, the following factors were examined sequentially: (1) Drug-matrix ratio: Three drug-to-matrix mass ratios were set: 1:5 (w / w), 1:10 (w / w), and 1:15 (w / w). The final drug loading and encapsulation efficiency of the microneedles were used as the core evaluation indicators. The evaluation indicators were: drug loading and encapsulation efficiency. (2) Solid content of the system: Based on a preferred formulation that mixes PLGA (30% w / v organic phase) and HA (10% w / v aqueous phase) at a mass ratio of 7:3, the final solid content of the entire mixture was adjusted to 15% (w / w), 20% (w / w), and 25% (w / w) by controlling the amount of organic solvent and water added. The integrity of the resulting microneedles and the sharpness of their tips were used as evaluation indicators.

[0086] (3) Types and dosages of plasticizers: The effects of plasticizers glycerin and polyethylene glycol 400 (PEG 400) were compared, with each plasticizer being evaluated at three addition levels: 5%, 10%, and 15% of the total matrix mass. The flexibility and single-needle breaking strength of the resulting microneedles were used as evaluation indicators.

[0087] 5.2 Box-Behnken Response Surface Optimization: Based on the results of the single-factor experiments above, the key variables that have the most significant impact on microneedle performance, such as drug loading level, system solid content level, plasticizer dosage level and its range, were selected. A multi-factor, multi-level experimental scheme was developed using the Box-Behnken experimental design method. Encapsulation efficiency, breaking strength, and 14-day cumulative release were simultaneously optimized as multiple response values ​​to determine the optimal formulation: drug-to-matrix mass ratio 1:10, system solid content 20% (w / v), glycerol addition 8%, active ingredient encapsulation efficiency >86%, and single-needle breaking strength >13.8 MPa.

[0088] Example 6: This example provides a specific illustration of the optimization of process parameters and sterilization process for the micromolding method used in this application.

[0089] 6.1 Core process route: The preparation process based on micromolding was established as follows: preparation and mixing of drug and matrix solution → vacuum degassing treatment → injection of polydimethylsiloxane (PDMS) microneedle mold → centrifugation-assisted filling → drying and curing under specific temperature and humidity conditions → demolding → sealing and storage of finished product.

[0090] 6.2 Key process parameters: (1) Centrifugation speed and time: The effects of centrifugation speeds of 2000 rpm, 3000 rpm, and 4000 rpm and centrifugation times of 5 min, 10 min, and 15 min on the integrity of the mixture filling the micropores of the mold tip were investigated. The forming condition of the tip was observed using a scanning electron microscope (SEM) to determine the optimal centrifugation parameters as a combination of 4000 rpm and 15 min, thereby achieving the best product forming rate.

[0091] (2) Drying temperature and humidity: The combined effects of different drying temperatures (25℃, 30℃, 35℃) and different ambient relative humidity levels (below 30% RH, about 50% RH) on the appearance of microneedles, whether they collapse or deform, and the stability of the loaded drug components were investigated to determine a suitable combination of drying process parameters.

[0092] (3) Demolding process: While keeping the microneedle array intact, we optimized the specific demolding techniques and timing through repeated experiments.

[0093] 6.3 Evaluation Indicators and Process Objectives: The core evaluation indicators in this embodiment are: the integrity of the microneedle tip filling observed under a scanning electron microscope (SEM), and the yield (%) of the entire batch. The goal of process optimization is to establish a standardized preparation operation process with clear steps, well-defined parameters, and good reproducibility, so that the yield of the final product batches remains stable at over 90%.

[0094] Example 7: This example tests the mechanical compression and puncture performance of the microneedles described in this application by measuring the compression force-displacement response law of microneedles with different prescriptions, so as to avoid the risk of broken needle residue during clinical puncture.

[0095] 7.1 Test instruments: STS 10 N microcomputer-controlled texture analyzer, pressure rate 10 mm / min, maximum test load 20 N; three independent microneedles were tested in parallel in each group.

[0096] Experimental groups: NC blank pure PLGA microneedles (negative control), Bateri7 whole extract drug-loaded microneedles (reference group), and WQH0.5M active composition of the present invention drug-loaded microneedles (experimental group).

[0097] Among them, the NC blank pure PLGA microneedles are a basic matrix control without hyaluronic acid and drugs, which is used to compare the mechanical advantages of the composite matrix; Bateri7 drug-loaded microneedles are traditional Mongolian medicine full compound drug-loaded microneedles, which are used for cross-sectional comparison of effects; WQH0.5M drug-loaded microneedles are drug-loaded microneedles of the quaternary active composition specified in this application.

[0098] 7.2 Evaluation Indicators: The performance evaluation criteria are to ensure that the microneedle array can effectively penetrate human skin in practical applications. The average single needle puncture force is > 0.05 N to ensure that it can effectively penetrate the stratum corneum of the skin.

[0099] Fracture force evaluation: After fixing the microneedle patch under test, the needle tip is pressed vertically against a hard metal plate at the same test speed. The load is continued until a sudden drop in force is detected, and the recorded initial peak force value is taken as the force at which the needle breaks.

[0100] The prepared microneedle patch was adhered to the sample stage using conductive tape, and after gold sputtering according to SEM standard operating procedures, it was placed in the SEM sample chamber. At different magnifications, such as 50x for observing the overall array and 200x and 500x for observing the needle details, the overall morphology, tip size, surface microtexture, and array uniformity of the microneedles were observed and photographed. The tested microneedle patch was horizontally fixed on the texture analyzer platform, the indenter was vertically aligned with the center area of ​​the array, a constant pressing rate of 10 mm / min was set, and the maximum test force was 20 N. The needle tip was vertically pressed against a skin simulation material, such as 8 layers of Parafilm® M sealing film. Force and displacement data were collected and recorded in real time, the maximum puncture force during the puncture process was acquired, and a force-displacement curve was plotted to obtain the attached... Figure 2 Each prescription was tested in parallel using three independent microneedle arrays to reduce random error in the experiment.

[0101] Figure 2 The mechanical compression performance test curves of microneedles with different prescriptions are shown. The horizontal axis represents the applied force (Force, unit: N), and the vertical axis represents the displacement (Displacement, unit: mm). The curves represent the force-displacement response of microneedles in the NC group (blank control group), Bateri7 group, and WQH-0.5M group, respectively. Depend on Figure 2It can be seen that within the tested force range of 0~20 N, the displacement of each group of microneedles increases with the increase of the applied force, and none of the three groups of microneedles broke within the test range; indicating that the microneedles did not undergo brittle fracture under the test conditions and have good mechanical integrity. Under the same applied force, the displacement response of the three groups of microneedles differs: the displacement of the NC group is slightly greater than that of the Bateri7 group and the WQH0.5M composition group, and the WQH0.5M composition group has the smallest deformation and stronger rigidity under the same force; it can be seen that the WQH composition composite matrix drug-loaded microneedles of the present invention have better mechanical rigidity than blank pure PLGA microneedles and higher structural stability. Therefore, it can be concluded that the PLGA / HA composite matrix drug-loaded microneedles have better mechanical rigidity than single PLGA blank microneedles and higher structural stability; its excellent mechanical strength can ensure that the microneedles do not break during skin puncture and eliminate the safety hazard of needle residue in the skin.

[0102] Example 8: AFM single-cell force spectrum bacterial-host adhesion test.

[0103] This embodiment verifies from a mechanobiological perspective that the active composition reduces the adhesion between Staphylococcus aureus and HaCaT keratinocytes, and supports the host-guided antibacterial mechanism based on in vitro antibacterial activity and cell infection models.

[0104] 8.1 Test Instruments: FluidFM-AFM single-cell force spectrometer, with a dedicated capture probe spring constant of 0.6 N / m and a cell capture negative pressure of -200 mbar; each group can detect no fewer than 30 paired single cells.

[0105] Cells and strains: Human immortalized HaCaT keratinocytes and Staphylococcus aureus ATCC25923.

[0106] 8.2 Experimental Grouping: The control group included blank infection, aconitine monotherapy group, quercetin monotherapy group, hydroxyalizarin monotherapy group, gallic acid monotherapy group, Bateri7 whole extract group, WQH-3.2 group (i.e., the high concentration group with WQH composition concentration of 3.2 µg / mL), and WQH-0.8 group (i.e., the low concentration group with WQH composition concentration of 0.8 µg / mL).

[0107] 8.3 Evaluation of in vitro antibacterial activity: (1) Inhibition zone method: The prepared drug-loaded microneedle patch was directly attached to the surface of an agar medium plate on which Staphylococcus aureus (ATCC 25923) bacterial suspension was evenly coated. After the plate was placed in a 37°C constant temperature incubator for 24 hours, it was taken out to observe and measure the diameter of the transparent inhibition zone formed around the patch.

[0108] (2) Determination of MIC and MBC using the microbroth dilution method: The extract of the drug-loaded microneedles was serially diluted. Following the standardized method recommended by the Clinical and Laboratory Standards Institute (CLSI), each dilution of the drug solution was added to LB medium containing bacteria. The medium was incubated at 37°C for 18–24 hours, and the lowest concentration at which no bacterial growth was observed visually was determined as the minimum inhibitory concentration (MIC). Samples were taken from all clear wells where no bacterial growth was observed and transferred to drug-free agar plates. The plates were then incubated at 37°C for another 24 hours, and the lowest drug concentration at which the colony count decreased by more than 99.9% was determined as the minimum bactericidal concentration (MBC).

[0109] 8.4 Evaluation of drug efficacy in cell infection models: (1) Construction of infection model: Immortalized human keratinocytes (HaCaT) were seeded into cell culture plates using standard methods. Once the cell confluence was greater than 80%, Staphylococcus aureus suspension (MOI=10) was added and incubated for 2 hours to successfully establish an in vitro cell infection model.

[0110] Bacterial invasion rate determination: The classic antibiotic protection assay was used. After intervention in each group, cells were first treated with a culture medium containing a high concentration of gentamicin (100 μg / mL) to completely kill bacteria attached to the extracellular environment. Subsequently, host cells were lysed using a mild cell lysis buffer to release viable bacteria that had invaded the cells. The lysis buffer was serially diluted and plated, incubated overnight at 37°C, and then colony counts (CFU) were performed to reflect the number of viable bacteria in the cells of each group and the corresponding bacterial invasion rate.

[0111] Cell viability assay: The CCK-8 assay was performed according to the kit instructions to determine the survival rate of host cells after intervention in each treatment group, and to evaluate the protective effect of different treatments on cells under infected conditions.

[0112] Procedure: A single Staphylococcus aureus bacillus is captured by negative pressure using a probe, which is then brought close to the HaCaT cell at a speed of 1 μm / s. After contact and resting for 30 seconds, the probe is withdrawn at a uniform speed. The system automatically records the average adhesion force between a single cell-bacteria pair, and statistical software is used to analyze differences between groups. This method is used to quantitatively detect the adhesion force between bacteria and host cells. The results are as follows: Figure 3 As shown.

[0113] Appendix Figure 3 The results of the bacterial-host cell adhesion test are shown in the image. The left side is a schematic diagram of the single-cell force spectrum test using atomic force microscopy (AFM), and the right side is a bar chart of the adhesion forces (Fad, unit: nN) for each group, including the Control group, Bateri7 100 group, Bateri7 35 group, WQH0.5M 3.2 group, and WQH0.5M 0.8 group. Figure 3 It was found that the adhesion column heights of the Bateri7 group, WQH-3.2 group, and WQH-0.8 group were all lower than those of the blank control group, with the WQH-3.2 group showing the most significant decrease. After treatment with the WQH composition, the adhesion force at the bacterial-host cell interface was significantly lower than that of untreated infected cells. The adhesion inhibition effect of the four monomers used individually was weaker than that of the quaternary WQH composition, indicating a synergistic effect among the components. The composition inhibits bacterial colonization by regulating the mechanical interaction at the bacterial-host cell interface and reducing adhesion force, which, unlike traditional direct-acting bactericidal antibiotics, can reduce the risk of bacterial resistance induction at the mechanistic level. The above results indicate that the active composition of the present invention can effectively reduce the adhesion force between bacteria and host cells, suggesting its potential to weaken bacterial colonization. The drug-loaded microneedles significantly reduce the adhesion force between bacteria and cells.

[0114] Example 9: Quantitative detection of HaCaT cell infection by flow cytometry.

[0115] This experiment quantitatively evaluated the ability of the WQH composition to inhibit Staphylococcus aureus from invading host keratinocytes at the cellular level, and quantified the proportion of bacteria invading cells.

[0116] 9.1 Experimental apparatus: BD FACSCalibur flow cytometer, 3 biological replicates per group; Cells / strains: HaCaT cells, Staphylococcus aureus ATCC25923; Cell modeling: HaCaT cells were plated with 80% confluence and Staphylococcus aureus MOI=10 were co-incubated for 2 h; gentamicin was used to kill extracellular free bacteria, and intracellular Staphylococcus aureus was FITC fluorescently labeled after cell lysis.

[0117] 9.2 Experimental Grouping: The study included four groups: a blank normal cell group, a simple bacterial control group, an infection control group, a Bateri 7-100 μg / mL group, a WQH 0.25M group, and a WQH 0.5M group. The blank normal cell group was a bacterial control group with no bacteria and no drug administration, serving as a cell baseline control. The simple bacterial control group contained only bacteria and no cells, excluding interference from bacterial fluorescence background. The infection control group consisted of bacteria-infected cells without drug intervention, serving as an infection baseline control. The Bateri 7-100 μg / mL group, the WQH 0.25M group, and the WQH 0.5M group were all drug intervention groups.

[0118] 9.3 The operation process is as follows: HaCaT cells were plated to 80% confluence and co-incubated with Staphylococcus aureus at MOI=10 for 2 h to construct a cell infection model. After drug intervention, gentamicin treatment was used to kill extracellular free bacteria, and cells were lysed to release intracellular bacteria. Flow cytometry analysis: FITC-labeled bacteria were analyzed using flow cytometry to detect the percentage of fluorescently positive cells and the formation of attached bacteria. Figure 5 Scatter plots and statistical histograms.

[0119] Figure 5 and Figure 12 The image shows the results of flow cytometry detection of bacterial infection in host cells. The top section is a scatter plot of SSC-A / FITC-A for each group, the middle section is a histogram of the corresponding FITC-A single parameter, and the bottom section is a bar chart of the bacterial infection rate (%) for each group. The groups include Control group, Bateri 7-100 μg / mL group, WQH-0.5M group, and WQH-0.25M group. Figure 5 It can be seen that the Control group had the highest proportion of fluorescently positive cells, while the WQH-0.5M group showed a significant leftward shift in fluorescence signal and a significant reduction in the number of positive cells; the WQH-0.25M group showed a weaker inhibitory effect than the WQH-0.5M group. These results indicate that, compared with the infected control group, the proportion of fluorescently labeled bacterial-positive host cells in the drug-loaded microneedle treatment group significantly shifted to the left, indicating a significant reduction in the bacterial invasion rate of host cells. This verifies that the microneedles of this application can effectively inhibit the invasion of Staphylococcus aureus into host HaCaT cells through their active ingredients. These quantitative results corroborate the AFM adhesion assay, demonstrating that reducing bacterial-cell interface adhesion is a core pathway to reducing intracellular bacterial invasion.

[0120] Example 10: HaCaT cell infection immunofluorescence staining observation experiment.

[0121] This experiment uses fluorescence imaging to visually demonstrate the inhibitory effect of the WQH composition on Staphylococcus aureus invasion of host cells, providing both qualitative and quantitative evidence in conjunction with flow cytometry.

[0122] 10.1 Experimental instrument: Inverted fluorescence microscope, with a uniform scale of 100 μm.

[0123] Staining reagents: DAPI-labeled cell nuclei (blue), FITC-labeled intracellular Staphylococcus aureus (green); 10.2 Experimental Grouping: The modeling and drug administration procedure was completely consistent with Example 9. Five fields of view were randomly selected from each group for uniform exposure and photography. The cell infection rate of each group was statistically analyzed. Uniform microscope exposure parameters and a uniform 100 μm shooting scale were used. Fields of view were randomly selected for photography, and the images were compiled into an appendix. Figure 6 .

[0124] like Figure 6 and Figure 13 The image shows immunofluorescence staining micrographs and quantitative analysis of bacterial infection in host cells. The left side displays fluorescence images of cells in each group (scale bar 100 μm), and the right side shows a bar chart of Staphylococcus aureus infection rates. The groups include Control group, Bateri 7-100 μg / mL group, WQH-0.5M group, and WQH-0.25M group. Figure 6 As can be seen from the fluorescence microscopy bar at 100 μm, the Control cells showed a dense concentration of green fluorescent spots, indicating a high number of intracellular bacteria. The WQH0.5M group showed a significant reduction in the number of green fluorescent spots, indicating the mildest infection. The right-hand bar chart shows that the Control group had the highest Staphylococcus aureus infection rate, with the infection rates of all treatment groups significantly lower than the Control group. Specifically, the WQH-0.5M and Bateri7-100 μg / mL groups showed significantly lower infection rates than the WQH-0.25M group, exhibiting superior inhibitory activity, with no significant difference between the two groups (labeled in ns). These results are consistent with the flow cytometry results, indicating that the active composition of this invention can effectively inhibit Staphylococcus aureus infection of host cells.

[0125] Example 11: Colony counting on in vitro antibacterial plates of IEC6 cells in co-culture.

[0126] This embodiment provides an in vitro, direct evaluation of the inhibitory activity of the WQH composition against Staphylococcus aureus proliferation, visually demonstrating the synergistic antibacterial effect of the multi-component combination. The test results correspond to the attached figures. Figure 7 .

[0127] 11.1 Experimental materials: IEC6 small intestinal epithelial cells, Staphylococcus aureus ATCC25923, constant temperature incubator, agar plates (scale bar 20 mm).

[0128] 11.2 Experimental groups: blank sterile culture medium group, simple bacterial suspension control group, Bateri7 100 μg / mL group, WQH 0.25M group, WQH 0.5M group.

[0129] Among them, the blank sterile culture medium plate group served as a sterile background control; the simple bacterial suspension Control group served as a baseline control without drugs and with normal bacterial growth; the Bateri7 100 μg / mL group, WQH 0.25M group, and WQH 0.5M group were the drug-induced antibacterial test groups, respectively.

[0130] 11.3 Standardized Complete Operation: 1) Dilute Staphylococcus aureus to a uniform standard concentration, and co-culture each group of drugs with the bacterial suspension at 37°C for 24 h; 2) Serially dilute the bacterial suspension, spread it evenly on agar plates, and incubate at 37°C at constant temperature overnight to count colonies; 3) Take photos of the plate colonies under uniform illumination with a uniform 20 mm scale, to obtain the attached Figure 7 .

[0131] Figure 7 is a photograph of the results of in vitro bacteriostatic plate colony counting. It shows the colony growth on agar plates of different treatment groups (Control, Bateri7 100, WQH0.5M, WQH0.25M) after co-culture of IEC6 cells with Staphylococcus aureus, the plate scale is 20 mm, by Figure 7 it can be seen that the plate of the Control pure bacterial suspension group is covered with a large number of colonies, with the largest number of colonies; the Bateri7 100 group follows, showing no obvious bacteriostatic effect compared with the control group; the number of colonies in the WQH-0.5M group and the WQH-0.25M group is significantly reduced, wherein the WQH-0.5M group has almost no colony growth, and has the optimal bacteriostatic effect. The above results indicate that, compared with the control group and Bateri7 100, the WQH composition exhibits extremely strong bacteriostatic ability at concentrations of 0.5M and 0.25M, and can effectively inhibit the in vitro growth of Staphylococcus aureus. It can be seen that the WQH quaternary compound composition of the present invention can significantly inhibit the in vitro proliferation of Staphylococcus aureus; the bacteriostatic activity of the WQH compound composition is superior to that of the single Mongolian medicine Bateri7 extract, and there is a synergistic bacteriostatic effect between the components; it can reduce the risk of cytotoxicity caused by the use of a single drug at a high dose.

[0132] Example 12: Safety evaluation of rat heart and whole body organs.

[0133] In this example, the left ventricular ejection fraction EF% of rats is detected by echocardiography, to evaluate the systemic toxicity of topical administration of WQH drug-loaded microneedles on the skin to the heart, verify the in vivo safety of the preparation, and conduct in vivo pharmacodynamic evaluation and biological safety evaluation on the microneedles prepared in the present application.

[0134] 12.1 Experimental animals: SPF grade SD female rats, weighing 180~220 g, animal production license SCXK (Beijing) 2019-0010; n=6 in each group; anesthetized by isoflurane gas anesthesia, all operations comply with the ethical specifications for experimental animals, and the detection instrument is Vevo 2100 small animal echocardiograph.

[0135] 12.2 Experimental groups: blank normal control group, infection model group, Bateri7 gradient concentration group (25 / 35 / 50 / 100 / 200 μg / mL), and WQH 0.5M gradient concentration group (0.4 / 0.8 / 1.6 / 3.2 / 6.4 μg / mL).

[0136] Among them, the blank normal control rat group was created without infection or drug administration, serving as a physiological baseline control; the infection model group was infected without effective drug intervention; the gradient Bateri7 group and the gradient WQH0.5M group were used to investigate the safety of different drug dosages.

[0137] 12.3 Test items: Ultrasound detection of left ventricular ejection fraction (EF); After the test, the heart, liver, and kidneys were dissected, weighed, and organ indices were calculated. After tissue fixation, H&E pathological sections were used to observe damage.

[0138] 12.4 Procedure: After anesthetizing the rats, the left ventricular ejection fraction (EF%) was measured using echocardiography. Six rats were tested in each group in parallel. The mean EF% of each group was calculated, and a statistical line graph was plotted. Figure 8 Simultaneous dissection of rat heart, liver, and kidney for pathological sectioning provides additional evidence of safety. Figure 8 The image shows the results of the cardiac safety evaluation in rats. The top image shows echocardiograms (M-mode) of rats in each group, and the bottom image shows a line graph of left ventricular ejection fraction (EF%) for each group. The groups include Control, Model, Bateri7 series concentration groups, and WQH0.5M series concentration groups. The EF% values ​​of rats in each group are similar, and the left ventricular ejection fraction (EF%) of rats in each group is within the normal physiological range, with no significant differences between groups. These results indicate that within the dosage range of this experiment, the active composition of the present invention has no significant adverse effects on cardiac function in rats and exhibits good cardiac safety.

[0139] There was no significant difference in cardiac ejection fraction between rats in all treatment groups and control rats; local skin administration of the drug-loaded microneedles of this patent showed no cardiotoxicity within the tested dose range; combined with the results of pathological sections of multiple organs, it was demonstrated that the systemic biocompatibility of local transdermal administration of the microneedles was good.

[0140] Biosafety assessment: (1) Observation of local skin irritation: Throughout the experiment, the condition of the local skin of rats in each group after microneedle application or drug application was observed at regular intervals each day. Local reactions such as erythema, edema, crusting, and desquamation were observed and recorded according to the skin irritation response scoring criteria.

[0141] (2) Systemic toxicity evaluation: General condition and weight monitoring: Throughout the experimental period, the mental state, spontaneous activity, food intake and water consumption of each group of rats were observed and recorded daily. At the same time, the weight changes of each rat were weighed and recorded regularly.

[0142] Organ Index and Histopathology: At the end of the observation period, all surviving rats were sacrificed. Major vital organs, including the heart, liver, and kidneys, were immediately dissected. After rinsing with physiological saline and blotting with filter paper, the wet weight of each organ was measured using a precision balance, and the organ index (organ wet weight mg / rat body weight g) was calculated. After weighing, each organ was also fixed in formalin and prepared into paraffin sections. Following routine H&E staining, a comprehensive histomorphological examination was performed by pathologists to assess for any drug-related toxicological changes in each organ.

[0143] Data analysis methods: All quantitative data are expressed as mean ± standard deviation (Mean ± SD). Data processing and statistical analysis were performed using professional statistical software (such as SPSS). When multiple group comparisons were required, one-way ANOVA was performed first. If the variances were homogeneous and the differences between groups were significant, post-hoc analysis with multiple comparisons was then performed using methods such as the Tukey test. A p-value < 0.05 was used as the threshold for determining statistical significance.

[0144] Example 13: Verification of transdermal absorption and epidermal cell attenuation of aconitine in WQ composition.

[0145] 13.1 Transdermal blood drug test in rats: The total loading of aconite in a single microneedle patch was 0.1–0.5 mg, administered via application to the back of rats. Blood samples were collected from the orbital fossa on days 1 and 3, and serum aconitine concentration was measured by HPLC. The blood drug concentration was below the poisoning threshold at all time points.

[0146] 13.2 HaCaT cell CCK toxicity test: At the same aconitine concentration, the cell survival rate of the quaternary compound group was significantly higher than that of pure aconitine monomer; quercetin and gallic acid have a synergistic detoxification effect, reducing the skin cell toxicity of aconitine and avoiding the safety risks of topical application.

[0147] Example 14: In vivo efficacy test of Staphylococcus aureus infection in rat skin.

[0148] The experimental animals, anesthesia methods, and ethical requirements are the same as in Example 12, with n=6 for each group.

[0149] Modeling procedure: Hair was removed from the back of the rat, the stratum corneum was slightly abraded with sandpaper, and sterile sandpaper was used on the hair-removed skin surface. The surface is gently and evenly abraded to disrupt the barrier integrity of the stratum corneum, creating a superficial wound. Subsequently, 20 μL of a pre-prepared fresh Staphylococcus aureus suspension (bacterial concentration approximately 1 × 10⁻⁶) is aspirated. 7 CFU (carbohydrate, volatile organic compounds) is evenly inoculated onto the abraded area. The inoculation site is then examined for redness, swelling, exudation, or other signs of acute local inflammation to confirm the infection model.

[0150] Experimental groups: blank normal rat group, infection model group, blank drug-free microneedle group, mupirocin ointment positive control group, low-dose drug-loaded microneedle group of WQH composition, and high-dose drug-loaded microneedle group of WQH composition. Among them, the blank normal non-invasive rat group served as a physiological baseline control; the infection model group was an artificially induced infection without effective drug intervention; the blank drug-free microneedle group was to exclude interference from the matrix excipients on wound bacteria; the mupirocin ointment group served as a positive control for first-line clinical topical antibiotics; and the low / high-dose drug-loaded microneedle group of WQH composition was the experimental formulation of this invention.

[0151] Dosage regimen: Dosing began 24 hours after the infection model was established. Microneedle patches were replaced every 48 hours; mupirocin ointment was applied twice daily, morning and evening, for 3 consecutive days.

[0152] Testing indicators: (1) Bacterial load in the wound: On the 1st, 2nd and 3rd day after administration, the whole layer of infected skin was aseptically taken, the tissue homogenate was serially diluted and plated to count CFU; the live bacterial load in the wound of the WQH composition group was significantly lower than that of the model group, and the antibacterial effect was comparable to that of mupirocin. (2) Macroscopic observation of wound healing: Daily changes in wound redness and swelling and area were photographed using a uniform scale; the wound healing and epithelialization speed of the WQH combination group was better than that of mupirocin ointment; (3) Histopathology and inflammatory factors: skin H&E and Masson collagen staining; ELISA detection of serum IL-6 and TNF-α. The WQH combination group showed significantly reduced inflammatory infiltration and better collagen repair.

[0153] Figure 9 Photographs showing bacterial load plate counts on infected skin wounds in rats. Figure 9 The image shows the colony counts obtained by serially diluting and plating skin tissue homogenates from infected sites after treatment for a certain period of time (Day 1-Day 3) in different treatment groups (Control, Infection model, Bateri7, monomeric combinations, and Mupirocin). The scale bar is 20 mm. Figure 9As can be seen, the number of colonies on the Infection Model group plates increased significantly over time, while the number of colonies in the Control group was extremely low. The number of colonies in the Bateri7 group, the monomer combination group, and the mupirocin group was significantly lower than that in the model group. The number of colonies in the WQH composition-loaded microneedle group was significantly reduced, and the antibacterial effect was close to that of the mupirocin positive control. The above results indicate that the composition of the present invention can effectively reduce the bacterial load on infected wounds and has a good in vivo antibacterial effect.

[0154] Experiment 15: Macroscopic observation experiment on wound healing in rats with infection.

[0155] The experiment provides a macroscopic and intuitive comparison of the effects of different treatments on the repair and promotion of Staphylococcus aureus-infected skin wounds, verifying the advantages of the formulation in promoting wound healing.

[0156] The materials, grouping, modeling, and drug administration procedures in this experiment were completely identical to those in Experiment 9, ensuring parallel control. The macroscopic condition of the wound was recorded using consistent and fixed lighting, a consistent scale, and consistent photographic timing. The photographs were then compiled into an appendix. Figure 10 The image shows a comparison of treatment effects regarding wound healing. Figure 10 These are photographs depicting the healing process of infected skin wounds in rats. They show the wound healing status of different treatment groups (Control, Infection model, Bateri7, single-component combination, Mupirocin) on Day 1 through Day 3. A scale is attached below each photograph. Figure 10 It was found that, within the same observation period, the wound area was significantly smaller than that of the infected Model group, and the redness and swelling inflammation subsided significantly, indicating that it had a wound-healing effect. The drug-loaded microneedles of the WQH composition can accelerate the reduction of redness and swelling in infected wounds and reduce the wound area; the host-guided antibacterial microneedles of this invention have a better effect on promoting wound healing than traditional mupirocin ointment; it is suitable for superficial skin infections and wound-associated infections induced by Staphylococcus aureus, and has clinical translation potential.

[0157] Example 16: In vitro sustained-release test of active ingredients in microneedles.

[0158] The sterilized WQH composition drug-loaded microneedles were immersed in a 37 ℃ pH 7.4 PBS sustained-release medium and continuously oscillated at a constant temperature. Samples were taken at 1 d, 3 d, 7 d, and 14 d, and the total content of the four active ingredients in the release medium was detected by HPLC to calculate the cumulative release rate.

[0159] Experimental results: 72% of the active ingredient was released cumulatively in 7 days, and the active ingredient was completely released in 14 days. The drug release rate matched the complete degradation cycle of the microneedles in 7-14 days, achieving simultaneous drug release during matrix degradation.

[0160] The above description is merely a few embodiments of this application and is not intended to limit this application in any way. Although this application discloses preferred embodiments as described above, it is not intended to limit this application. Any changes or modifications made by those skilled in the art without departing from the scope of the technical solution of this application using the disclosed technical content are equivalent to equivalent implementation cases and fall within the scope of the technical solution.

Claims

1. A targeted antibacterial biodegradable microneedle, characterized in that, The microneedle is made of a biodegradable matrix material, and the active ingredient is embedded in the microneedle. The active ingredient is configured to be released during needle degradation. The active ingredient is a host-directed antimicrobial composition. The active ingredient has a synergistic antimicrobial effect with a combined inhibitory concentration index ≤0.5, and the property of inhibiting bacterial colonization by regulating the mechanical interaction between host cells and bacteria and reducing the adhesion of bacteria to host cells.

2. The targeted antibacterial biodegradable microneedle according to claim 1, characterized in that, The active ingredient is derived from the Mongolian medicine Bater-7, and the active ingredient is a composition of alkaloids, flavonoids, anthraquinones and phenolic acids. The alkaloids include aconitine, the flavonoids include quercetin, the anthraquinones include hydroxyalizarin, and the phenolic acids include gallic acid, and the mass ratio of aconitine, quercetin, hydroxyalizarin to gallic acid is (2-4):(2-4):(2-4):(1-2).

3. The targeted antibacterial biodegradable microneedle according to claim 1, characterized in that, The matrix material is a mixture of polylactic acid-glycolic acid copolymer (PLGA) and hyaluronic acid (HA), wherein the mass ratio of PLGA to HA is (8:2) to (7:3).

4. The targeted antibacterial biodegradable microneedle according to claim 3, characterized in that, The matrix material also contains a plasticizer, which is glycerol or polyethylene glycol, and the amount of plasticizer added is 5% to 10% of the total mass of the matrix material.

5. The targeted antibacterial biodegradable microneedle according to claim 3, characterized in that, The polylactic acid-glycolic acid copolymer (PLGA) has a weight-average molecular weight of 15 kDa to 30 kDa and a molar ratio of lactic acid to glycolic acid of 50:50 to 75:

25.

6. The microneedle according to claim 1, characterized in that, The microneedles were completely degraded in phosphate buffer at pH 7.4 at 37°C within 7 to 14 days.

7. A method for preparing the biodegradable microneedles according to any one of claims 1 to 6, characterized in that, Includes the following steps: S1, mix the matrix material containing the needle with the active ingredient to obtain a blend solution; S2, After centrifuging and degassing the blended solution, inject it into the microneedle mold; S3 is dried and cured at 20℃~35℃ and relative humidity of 30%~55%. S4, demolding to obtain a biodegradable microneedle array.

8. The method for preparing a targeted antibacterial biodegradable microneedle according to claim 7, characterized in that, In S3, the drying temperature is 25±2℃ and the drying time is 6 hours.

9. An application of the targeted antibacterial biodegradable microneedles according to any one of claims 1 to 6, characterized in that, The application of the biodegradable microneedles in the treatment of skin infections.

10. The application of a targeted antibacterial biodegradable microneedle according to claim 9, characterized in that, The bacteria used to treat skin infections are Staphylococcus aureus or Escherichia coli.